お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:動静脈瘻の世界市場:2020年~2027年
市場調査レポート
商品コード
994979

動静脈瘻の世界市場:2020年~2027年

Global Arteriovenous Fistula Market, Size, Share, Opportunities and Forecast, 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
動静脈瘻の世界市場:2020年~2027年
出版日: 2021年04月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

動静脈瘻とは、静脈と動脈の間の異常な連結部分によって引き起こされる血液供給の遮断のことです。動静脈瘻治療市場は、主要企業が光線力学療法、抗血管新生療法、その他の硬化療法などの新しい治療法を開発し、予測期間中に拡大すると予想されています。

当レポートでは、世界の動静脈瘻市場について調査分析し、業界分析、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 世界の動静脈瘻市場の調査手法と調査範囲

第2章 世界の動静脈瘻市場:市場定義と市場概要

第3章 世界の動静脈瘻市場:エグゼクティブサマリー

第4章 世界の動静脈瘻市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 影響分析

第5章 世界の動静脈瘻市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 世界の動静脈瘻市場:COVID-19の分析

  • 市場に対するCOVID-19の分析
  • COVID-19における価格動向
  • 需給スペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の動静脈瘻市場:タイプ別

  • イントロダクション
  • タイプセグメント別の市場規模分析・前年比成長率分析
  • タイプセグメント別の市場魅力指数
    • Radial Cephalic fistula
    • Brachial Cephalic
    • Brachial Basilic Transposition

第8章 世界の動静脈瘻市場:治療法別

  • イントロダクション
  • 治療法セグメント別の市場規模分析・前年比成長率分析
  • 治療法セグメント別の市場魅力指数
    • 血管内塞栓術
    • マイクロサージェリー
    • 定位放射線治療

第9章 世界の動静脈瘻市場:地域別

  • イントロダクション
  • 地域別の市場規模分析・前年比成長率分析
  • 地域別の市場魅力指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋地域
  • 中東・アフリカ

第10章 世界の動静脈瘻市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • M&A分析

第11章 世界の動静脈瘻市場:企業プロファイル

  • Pervasis Therapeutics, Inc.
  • Proteon Therapeutics, Inc.
  • Medtronic,
  • Cook Medical
  • Fresenius Medical Care AG & Co. KGaA
  • Poly Medicure Limited
  • Becton Dickinson and Company
  • Braun Melsungen Ag
  • Teleflex Incorporated
  • NxStage Medical, Inc.、など

第12章 世界の動静脈瘻市場:重要考察

第13章 世界の動静脈瘻市場:DataM Intelligence

目次

Global Arteriovenous Fistula Market is segmented By Type (Radial Cephalic fistula, Brachial Cephalic, Brachial Basilic Transposition), By Treatment Methods (Endovascular embolization, Microsurgery, Stereotactic radiosurgery), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Arteriovenous Fistula Market is expected to grow at a CAGR during the forecasting period (2020-2027).

The interruption of blood supply caused by an irregular link between a vein and an artery is known as an arteriovenous fistula. Blood passes straight from lungs to veins in the event of an arteriovenous fistula, bypassing capillaries. Capillary tissues thus obtain smaller supplies of oxygen (blood supply) and raise the risk of complications with blood pressure. Fistulas between the arteries and veins may be congenital or inherited. Congenital fistula occurs during embryonic development and mainly affects blood vessels in the lower extremities. While acquired fistula typically happens when veins and arteries are impaired, between two parallel vein and artery connections, the healing process results. Further, On the arms, kidney, brain, or certain parts of the legs, the arteriovenous fistula is formed. Penetrating damage, arterial vein breakup, and inflammatory necrosis of adjacent veins all increase the risk of an arteriovenous fistula.

The global arteriovenous fistula market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Source: DataM Intelligence Analysis (2019)

Market Dynamics

Owing to the consistent efforts of key players to develop novel therapeutics for the treatment of arteriovenous fistula, the global arteriovenous fistula market is seeing fast growth. In April 2017, for instance, Shire announced a phase II trial to determine the effectiveness and safety of SRM003 (Vascugel) in arteriovenous fistula and end-stage renal disease patients. Furthermore, the presence of a vast number of therapeutics in the research pipeline, as well as optimistic government policies, would improve the demand for arteriovenous fistula over the forecast period. Pervasis Therapeutics, Inc., for example, obtained FDA approval in February 2010 for a pivotal phase III trial of Vascugel, an investigational novel medication for the treatment of hemodialysis access graft failure. This forms of regulatory approval and policies would also offer a stable forum to expand this sector and hence accelerate the development of the arteriovenous fistula market. It is expected that the demand for the treatment of arteriovenous fistulas will expand substantially in the coming years. Market players are improving their treatment approaches, such as antiangiogenic therapy, photodynamic therapy and an additional form of sclerotherapy, as factors that contribute to this development. The development of an appropriate therapeutic plan for the full treatment of the condition is a challenging process that is still in progress. This generated the need for new technologies and improvements in the treatment process for industry leaders to come up with. The market's development is hampered by a lack of awareness about the disease.

Growing demand for advanced treatment methods

Over the projected period, the arteriovenous fistulas care market is expected to expand as players develop new treatment methods such as photodynamic therapy, antiangiogenic therapy, and other sclerotherapy methods. The successful form of therapy for a complete recovery in a simple way is still in the process of development, which inspires players to come up with innovative treatment technologies. Further, growing FDA approvals for Noninvasive Devices for Arteriovenous Fistula Creation has resulted in the growth of the market over the foerecast period. For instance, in June 2018, The FDA has permitted marketing approval for 2 percutaneous arteriovenous fistula (AVF) catheter-based systems: the Ellipsys Vascular Access System (Avenu Medical) and the everlinQ endoAVF system (TVA Medical). Both the everlinQ endoAVF Device, which uses two catheters, and the Ellipsys Vascular Access System, which uses a single catheter, are equipped to establish arteriovenous (AV) fistulas by fusing blood vessels in a patient's arm using an energy source. Moreover, The optimal access for hemodialysis transmission is known to be an autogenous arteriovenous fistula. The surgical development of an arteriovenous fistula, on the other hand, is synonymous with less-than-ideal technical performance, and numerous procedures are often required to aid maturation or preserve early patency. With these deficiencies, many new methods are now under study that can enhance surgical procedures and/or performance. Minimally invasive new system manufacturing methods are being studied, with early research findings available.

Lack of effective therapeutics

The lack of effective therapeutics that can address the particular cause of arteriovenous fistula, on the other hand, would restrict the market's expansion. Often recovery may take longer than expected, or access can fail to mature. Further, to access the AV fistula for dialysis, needles are required.

COVID-19 Impact Analysis

The global healthcare system has been challenged by a recent epidemic known as coronavirus disease 2019 (COVID-19). More than 1,000,000 positive cases had been registered by the beginning of April, with 51,737 deaths. During a pandemic, a global solution to sustain the healthcare infrastructure is crucial. The primary justification for delaying elective treatments is to ensure that the healthcare system can keep up with the pandemic. There have been various questions over whether to postpone vascular operations and the safety steps needed during the care of a patient with COVID-19. Moreover, hemodialysis vascular accesses are considered the patient's lifeline, and their upkeep is vital for care consistency. The Brazilian Society of Nephrology developed these recommendations for healthcare facilities, elaborating on the value of conducting procedures for the planning and protection of vascular accesses, following the lead of organizations in other countries affected by the COVID-19 pandemic. Non-elective treatments, as well as the transition from the use of non-tunnel catheters to tunnel catheters causing less morbidity, are the development of conclusive accesses for hemodialysis, grafts and arteriovenous fistulas.

Market Segment Analysis

Based on the type, the arteriovenous fistula market has been classified into radial cephalic fistula, brachial cephalic,  brachial basilic transposition.

During the forecast period, the radial cephalic fistula segment is expected to rise at the fastest CAGR.

As part of the Kidney Disease Outcomes Quality Initiative (KDOQI), the 2006 recommendations suggested by the National Kidney Foundation suggest that a radiocephalic fistula be the first alternative for fistula creation. This is because the radiocephalic fistula has a lower rate of steal syndrome than upper arm fistulas and because developing this forearm fistula retains the possibility of creating a more proximal fistula in the future if this access fails. The maturation rate for radiocephalic fistulas, however, is low  with one analysis finding that up to two-thirds of radiocephalic fistulas have not matured.

The global arteriovenous fistula market is segmented on the basis of treatment methods, which includes endovascular embolization, microsurgery, stereotactic radiosurgery.

Endovascular embolization segment is expected to account significant market share in Arteriovenous Fistula market.

Endovascular embolization is a recent therapeutic procedure for arteriovenous malformations (AVM). During this procedure, a catheter is implanted through the groin into the arteries in the brain that contribute to the AVM, and a material is injected into the arteries. This injection blocks the artery, limiting blood flow into the AVM. Usually, endovascular embolization alone does not remove the AVM and is, thus, almost exclusively used as a preliminary step in either microsurgical resection or stereotactic radiotherapy preparation.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Based on geography, the study analyzes the arteriovenous fistula market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America Region is expected to dominate the global Arteriovenous Fistula market

Geographically, owing to positive measures by the U.S. government in order to create new therapeutics for arteriovenous fistula disease, North America leads the worldwide arteriovenous fistula market. Europe is the second-largest market for arteriovenous fistulas after the U.S. The growth of this market in Europe is mainly due to the growing occurrence of arteriovenous fistula in this region, combined with a strong demand for arteriovenous fistula therapy. Moreover, owing to growing healthcare understanding among the patient population, Asia-Pacific countries are the developing countries for the worldwide arteriovenous fistula industry.

Competitive Landscape

The arteriovenous fistula market is moderately competitive, owing to the presence of major market players in the key regions such as US, China, India and others. The key arteriovenous fistula players which are contributing to the growth of the global market include Dentsply Sirona, Danaher Corporation, Johnson & Johnson, Medtronic, Zimmer Biomet, BioHorizons IPH, Inc., RTI Surgical Holding Inc., Straumann Group, Lifenet Health, Dentium among others. The major players are adopting new product launch and expansion strategies for global growth in the arteriovenous fistula market.   

Medtronic:

Medtronic plc is an American medical technology corporation that produces the majority of its U.S. healthcare system revenue and profit but is based in the Republic of Ireland. The Medtronic's organizational and executive headquarters are based in Fridley, Minnesota. In 2015, Medtronic acquired Irish-tax licensed Covidien (a U.S. tax inversion to Ireland since 2007), which enabled Medtronic to transfer its legal registration from the U.S. to Ireland. The Medtronic serves in 140 countries and employs more than 100,000 workforces. Medtronic has four main business units: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Why Purchase the Report?

Visualize the arteriovenous fistula market segmentation composition by form, application, and region, highlighting the critical commercial assets and players.

Identify commercial opportunities in the arteriovenous fistula market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of arteriovenous fistula market - level 3 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players.

The global arteriovenous fistula market report would provide access to an approx. 48 market data table, 43 figures and 237 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Suggestions for Related Market Report:

Global Biomaterials Market

Global Anticoccidial Drugs Market

Global Healthcare Analytics Market

Table of Contents

Table of Contents

Global Arteriovenous Fistula Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Global Arteriovenous Fistula Market - Market Definition and Overview

Global Arteriovenous Fistula Market - Executive Summary

Market Snippet by Type

Market Snippet by Treatment Methods

Market Snippet by Region

Global Arteriovenous Fistula Market - Market Dynamics

Market Impacting Factors

Drivers

Growing demand for advanced treatment methods

Restraints:

Lack of effective therapeutics

Impact Analysis

Global Arteriovenous Fistula Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Value Chain Analysis

PEST Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Patent Trends

Global Arteriovenous Fistula Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Global Arteriovenous Fistula Market - By Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment

Market Attractiveness Index, By Type Segment

Radial Cephalic fistula

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Brachial Cephalic

Brachial Basilic Transposition

Global Arteriovenous Fistula Market - By Treatment Methods

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods Segment

Market Attractiveness Index, By Treatment Methods Segment

Endovascular embolization

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Microsurgery

Stereotactic radiosurgery

Global Arteriovenous Fistula Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Methods

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Global Arteriovenous Fistula Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Global Arteriovenous Fistula Market- Company Profiles

Pervasis Therapeutics, Inc.

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

Proteon Therapeutics, Inc.

Medtronic,

Cook Medical

Fresenius Medical Care AG & Co. KGaA

Poly Medicure Limited

Becton Dickinson and Company

Braun Melsungen Ag

Teleflex Incorporated

NxStage Medical, Inc.(*LIST NOT EXHAUSTIVE)

Global Arteriovenous Fistula Market - Premium Insights

Global Arteriovenous Fistula Market - DataM Intelligence Analysis

Appendix

About Us and Services

Contact Us

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.